effect of Nervoxin on hepatic clearance of 99mTc-Sestamibi
Phase 2
Recruiting
- Conditions
- Myocardial perfusion.Chronic ischemic heart disease
- Registration Number
- IRCT20200803048277N1
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
All patients except patients taking drugs that interact with nevroxin, such as digoxin, warfarin, theophylline, etc.
All patients except those with known hepatic and renal failure, patients with coagulation problems and heart disease.
Exclusion Criteria
Patients taking drugs that interact with nevroxin, such as digoxin, warfarin, theophylline, etc.
People with known hepatic and renal failure, patients with coagulation problems and heart patients
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 99mTc-MIBI accumulation in liver. Timepoint: 24 hours after receiving the last dose of Nervoxin. Method of measurement: Imaging with gamma camera.;Heart to liver activity ratio. Timepoint: 24 hours after receiving the last dose of Nervoxin. Method of measurement: Imaging with gamma camera.
- Secondary Outcome Measures
Name Time Method Difference Score in liver clearance of 99mTc-MIBI between control and intervention groups. Timepoint: After myocardial perfusion scan. Method of measurement: Imaging with gamma camera.